BACE2 as a new diabetes target: A patent review (2010-2012)

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 5, 2013, Pages 649-663

  Southan, Christopher ^a  

^a TW2Informatics Ltd   (Sweden)

Author keywords

BACE1; BACE2; Diabetes; IC50s; Inhibitors; TMEM27

Indexed keywords

1,3 OXAZINE DERIVATIVE; AMIDE; ANTIDIABETIC AGENT; ASPARTIC PROTEINASE INHIBITOR; BETA SECRETASE 1; BETA SECRETASE 2; BETA SECRETASE 2 INHIBITOR; HETEROCYCLIC COMPOUND; PYRIMIDINE DERIVATIVE; SULFONE DERIVATIVE; THIAZEPINE DERIVATIVE; THIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

DRUG INDUSTRY; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG TARGETING; GLUCOSE METABOLISM; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATENT; REVIEW; STRUCTURE ACTIVITY RELATION;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; MOLECULAR TARGETED THERAPY; PATENTS AS TOPIC;

EID: 84876545164     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.780032     Document Type: Review

References (56)

1. Lam DW, LeRoith D. The worldwide diabetes epidemic. Curr Opin Endocrinol Diabetes Obes 2012;19:93-6
2. El-Kaissi S, Sherbeeni S. Pharmacological management of type 2 diabetes mellitus: an update. Curr Diabetes Rev 2011;7:392-405
3. Esterhazy D, Stutzer I, Wang H, et al. Bace2 is a beta cell-enriched protease that regulates pancreatic beta cell function and mass. Cell Metab 2011;14:365-77
4. Akpinar P, Kuwajima S, Krutzfeldt J, Stoffel M. Tmem27: a cleaved and shed plasma membrane protein that stimulates pancreatic beta cell proliferation. Cell Metab 2005;2:385-97
5. Finzi G, Franzi F, Placidi C, et al. BACE2 is stored in secretory granules of mouse and rat pancreatic beta cells. Ultrastruct Pathol 2008;32:246-51
6. Hussain I, Powell D, Howlett DR, et al. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci 1999;14:419-27 (Pubitemid 30026585)
7. Vassar R, Bennett B, Babu-Khan S, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science (New York, N.Y.) 1999;286:735-41
8. Yan R, Bienkowski M, Shuck M, et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 1999;402:533-7
9. Sinha S, Anderson J, Barbour R, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 1999;402:537-40
10. Hussain I, Powell DJ, Howlett DR, et al. ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site. Mol Cell Neurosci 2000;16:609-19 (Pubitemid 32001309)
11. Lin X, Koelsch G, Wu S, et al. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Nat Acad Sci USA 2000;97:1456-60 (Pubitemid 30118462)
12. Acquati F, Accarino M, Nucci C, et al. The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the down critical region. FEBS Lett 2000;468:59-64 (Pubitemid 30101682)
13. Farzan M, Schnitzler C, Vasilieva N, et al. BACE2, a beta-secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. Proc Nat Acad Sci USA 2000;97:9712-17 (Pubitemid 30650841)
14. Beecham S. Aspartic proteinase 2 (ASP2). EP0855444; 1997
15. Beecham S. Aspartic protease ASP1. EP0848062; 1998
16. Ghosh AK, Brindisi M, Tang J. Developing beta-secretase inhibitors for treatment of Alzheimer's disease. J Neurochem 2012;120(Suppl):71-83
17. Probst G, Xu YZ. Small-molecule BACE1 inhibitors: a patent literature review (2006-2011). Expert Opin Ther Pat 2012;22:511-40
18. Fleck D, Garratt A, Haass C, Willem M. BACE1 dependent neuregulin proteolysis. Curr Alzheimer Res 2012;9(2):178-83
19. EPO-Espacenet. Available from: http://worldwide.espacenet.com/ advancedSearch? locale=en-EP [Acessed January 2013]
20. WIPO PATENTSCOPE. Available from: http://patentscope.wipo.int/search/en/ search.jsf [Acessed January 2013]
21. FPO IP Research & Communities. Available from: http://www. freepatentsonline.com/[Acessed January 2013]
22. Europe PubMed Central. Available from: http://europepmc.org/[Acessed January 2013]
23. SureChemOpen. Available from: https://open.surechem.com/en/[Acessed January 2013]
24. Southan C. InChI in the wild: an Assessment of InChIKey searching in Google. J Cheminform 2013;5:10
25. The PubChem Project. Available from: http://pubchem.ncbi.nlm.nih.gov/ [Acessed January 2013]
26. ChEMBLdb. Available from: https://www.ebi.ac.uk/chembldb/index.php [Acessed January 2013]
27. Ostermann N, Eder J, Eidhoff U, et al. Crystal structure of human BACE2 in complex with a hydroxyethylamine transition-state inhibitor. J Mol Biol 2006;355:249-61 (Pubitemid 41774129)
28. Novartis. Three-dimensional structure of the human aspartyl protease beta-site amyloid precursor-protein-cleaving enzyme 2 (BACE2), methods and use thereof. WO2006018287; 2006
29. Hoffman-La Roche. Screening assays for the identification of BACE2 inhibitors. WO2010063640; 2010
30. ETH-Zurich. Screening assay for metabolic disease therapeuticals. WO2010063718; 2010
31. Stachel SJ, Coburn CA, Steele TG, et al. Conformationally biased P3 amide replacements of beta-secretase inhibitors. Bioorg Med Chem Lett 2006;16:641-4 (Pubitemid 43014850)
32. Astex/AstraZeneca. Substitute amino compounds and uses thereof. WO2006041404; 2006
33. Shionogi. Aminodihydrothiazine derivative. WO2007049532; 2007
34. Hoffman-La Roche. 2-Aminodihydro [1, 3] thiazines as BACE2 inhibitors for the treatment of diabetes. WO2011029803; 2011
35. Hoffman-La Roche. Dihydropyrimidinones for use as BACE2 inhibitors. WO2010128058; 2010
36. Hoffman-La-Roche/Sienna Biotech. 3-Amino-5-phenyl-5,6-dihydro-2H-[1,4] oxazine derivatives. WO2011020806; 2010
37. Hoffman-La Roche. Amino oxazine derivatives. WO2011070029; 2011
38. Hoffman-La Roche/Sienna Biotech. 2-Amino-5, 5-difluoro-5, 6-dihydro-4Hoxazines as BACE1 and/or BACE2 inhibitors. WO2011069934; 2011
39. Hoffman-La Roche. BACE inhibitors for use in the treatment of diabetes. WO2012028563; 2012
40. Novartis. BACE-2 inhibitors for the treatment of metabolic disorders. WO2012095521; 2012
41. Hoffman-La Roche. Oxazine derivatives and their use as BACE inhibitors for the treatment of neurological disorders. WO2011009943; 2011
42. Novartis. Novel heterocyclic derivatives and their use in the treatment of neurological disorders. WO2012095469; 2012
43. Hoffman-La Roche. 1,4 Thiazepines/sulfones as BACE1 and/or BACE2 inhibitors. WO2012119883; 2012
44. Hoffman-La Roche/Sienna Biotech. 1,3 Oxazines as BACE1 and/or BACE2 inhibitors. WO2012139993; 2012
45. Schering. 5-Substituted iminothiazines, mono-and dioxides as BACE inhibitors, compositions and use. WO2012139425; 2012
46. Schering. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use. US20120183563; 2012
47. Esterhazy D, Akpinar P, Stoffel M. Tmem27 dimerization, deglycosylation, plasma membrane depletion, and the extracellular Phe-Phe motif are negative regulators of cleavage by Bace2. Biol Chem 2012;393:473-84
48. Casas S, Casini P, Piquer S, et al. BACE2 plays a role in the insulin receptor trafficking in pancreatic beta-cells. Am J Physiol Endocrinol Metab 2010;299:E1087-95
49. Meakin PJ, Harper AJ, Hamilton DL, et al. Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice. Biochem J 2012;441:285-96
50. Dominguez D, Tournoy J, Hartmann D, et al. Phenotypic and biochemical analyses of BACE1-and BACE2-deficient mice. J Biol Chem 2005;280:30797-806 (Pubitemid 41291810)
51. Van Bebber F, Hruscha A, Willem M, et al. Loss of Bace2 in zebrafish affects melanocyte migration and is distinct from Bace1 knock out phenotypes. J Neurochem 2013; Accepted Article
52. Cruchaga C, Haller G, Chakraverty S, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS One 2012;7(5):10
53. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012;488:96-9
54. Southan C, Boppana K, Jagarlapudi SAA, Muresan S. Analysis of in vitro bioactivity data extracted from drug discovery literature and patents: ranking 1654 human protein targets by assayed compounds and molecular scaffolds. J Cheminform 2011;3:14
55. Abdul-Hay SO, Sahara T, McBride M, et al. Identification of BACE2 as an avid beta-amyloid-degrading protease. Mol Neurodegener 2012;7:46
56. Luchsinger JA. Type 2 diabetes and cognitive impairment: linking mechanisms. J Alzheimer's Dis 2012;30(Suppl):2